Hims & Hers’ shares shot up after it said it would start selling a version of Wegovy
Jab makers fall behind Moderna in post-pandemic market with disappointing results
Administration claims victory in talks to cut the costs of 10 critical medicines
Doblin leaves Lykos Therapeutics board after work on treatment for PTSD suffered setback from FDA ruling
Leading producer says it needs orders to ramp up supply with outbreaks surging in central and east Africa
The Food and Drug Administration’s rejection of MDMA-assisted therapy is a missed opportunity
The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment
Merseyside plant had been offered £65mn for redevelopment but review looks to reduce figure to £40mn
Drugmaker has benefited from its bet on developing a portfolio of cancer drugs
Pharma groups and patients say guidance prioritising mass trials threaten drug development
Drugmakers will receive flat fees for new medicines in push to avoid encouraging overuse
Decision a setback for Lykos Therapeutics and psychedelic treatment aimed at 13mn Americans with PTSD
Shares soar as ‘strong performance’ of Mounjaro and Zepbound medicines underpin jump in revenue
Nice’s backing for Casgevy comes after UK became first country to give drug regulatory approval
Pharma companies are moving up the supply chain to secure radioactive materials for a new form of drugs
Shares in Danish drugmaker fall after second-quarter sales and profits fall short of forecasts
Swiss drugmaker examines options for Flatiron Health after acquisition has disappointed
Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Weight loss group announces overhaul to stay relevant amid boom in demand for new medications
For years, the process for developing and testing new drugs has focused disproportionately on male bodies — to the detriment of female patients
UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs
Nice blames cost for not recommending Enhertu, which has helped patients in clinical trials live longer
Swiss drugmaker unveils promising data for obesity drug
Extreme shortages of actinium are holding up the promising field of radiopharmaceuticals
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
